Copyright Reports & Markets. All rights reserved.

Global Bile Duct Cancer Drug Market Research Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Bile Duct Cancer Drug Market Overview

      • 1.1 Product Overview and Scope of Bile Duct Cancer Drug
      • 1.2 Bile Duct Cancer Drug Segment by Type
        • 1.2.1 Global Bile Duct Cancer Drug Production Growth Rate Comparison by Type (2014-2025)
        • 1.2.2 Cabozantinib S-malate
        • 1.2.3 Elpamotide
        • 1.2.4 Exatecan Mesylate
        • 1.2.5 LY-2801653
        • 1.2.6 NUC-1031
        • 1.2.7 Others
      • 1.3 Bile Duct Cancer Drug Segment by Application
        • 1.3.1 Bile Duct Cancer Drug Consumption Comparison by Application (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Clinic
        • 1.3.4 Others
      • 1.3 Global Bile Duct Cancer Drug Market by Region
        • 1.3.1 Global Bile Duct Cancer Drug Market Size Region
        • 1.3.2 North America Status and Prospect (2014-2025)
        • 1.3.3 Europe Status and Prospect (2014-2025)
        • 1.3.4 China Status and Prospect (2014-2025)
        • 1.3.5 Japan Status and Prospect (2014-2025)
        • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
        • 1.3.7 India Status and Prospect (2014-2025)
      • 1.4 Global Bile Duct Cancer Drug Market Size
        • 1.4.1 Global Bile Duct Cancer Drug Revenue (2014-2025)
        • 1.4.2 Global Bile Duct Cancer Drug Production (2014-2025)

      2 Global Bile Duct Cancer Drug Market Competition by Manufacturers

      • 2.1 Global Bile Duct Cancer Drug Production Market Share by Manufacturers (2014-2019)
      • 2.2 Global Bile Duct Cancer Drug Revenue Share by Manufacturers (2014-2019)
      • 2.3 Global Bile Duct Cancer Drug Average Price by Manufacturers (2014-2019)
      • 2.4 Manufacturers Bile Duct Cancer Drug Production Sites, Area Served, Product Types
      • 2.5 Bile Duct Cancer Drug Market Competitive Situation and Trends
        • 2.5.1 Bile Duct Cancer Drug Market Concentration Rate
        • 2.5.2 Bile Duct Cancer Drug Market Share of Top 3 and Top 5 Manufacturers
        • 2.5.3 Mergers & Acquisitions, Expansion

      3 Global Bile Duct Cancer Drug Production Market Share by Regions

      • 3.1 Global Bile Duct Cancer Drug Production Market Share by Regions
      • 3.2 Global Bile Duct Cancer Drug Revenue Market Share by Regions (2014-2019)
      • 3.3 Global Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.4 North America Bile Duct Cancer Drug Production
        • 3.4.1 North America Bile Duct Cancer Drug Production Growth Rate (2014-2019)
        • 3.4.2 North America Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.5 Europe Bile Duct Cancer Drug Production
        • 3.5.1 Europe Bile Duct Cancer Drug Production Growth Rate (2014-2019)
        • 3.5.2 Europe Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.6 China Bile Duct Cancer Drug Production (2014-2019)
        • 3.6.1 China Bile Duct Cancer Drug Production Growth Rate (2014-2019)
        • 3.6.2 China Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
      • 3.7 Japan Bile Duct Cancer Drug Production (2014-2019)
        • 3.7.1 Japan Bile Duct Cancer Drug Production Growth Rate (2014-2019)
        • 3.7.2 Japan Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)

      4 Global Bile Duct Cancer Drug Consumption by Regions

      • 4.1 Global Bile Duct Cancer Drug Consumption by Regions
      • 4.2 North America Bile Duct Cancer Drug Consumption (2014-2019)
      • 4.3 Europe Bile Duct Cancer Drug Consumption (2014-2019)
      • 4.4 China Bile Duct Cancer Drug Consumption (2014-2019)
      • 4.5 Japan Bile Duct Cancer Drug Consumption (2014-2019)

      5 Global Bile Duct Cancer Drug Production, Revenue, Price Trend by Type

      • 5.1 Global Bile Duct Cancer Drug Production Market Share by Type (2014-2019)
      • 5.2 Global Bile Duct Cancer Drug Revenue Market Share by Type (2014-2019)
      • 5.3 Global Bile Duct Cancer Drug Price by Type (2014-2019)
      • 5.4 Global Bile Duct Cancer Drug Production Growth by Type (2014-2019)

      6 Global Bile Duct Cancer Drug Market Analysis by Applications

      • 6.1 Global Bile Duct Cancer Drug Consumption Market Share by Application (2014-2019)
      • 6.2 Global Bile Duct Cancer Drug Consumption Growth Rate by Application (2014-2019)

      7 Company Profiles and Key Figures in Bile Duct Cancer Drug Business

      • 7.1 Ariad Pharmaceuticals, Inc.
        • 7.1.1 Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Production Sites and Area Served
        • 7.1.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.1.3 Ariad Pharmaceuticals, Inc. Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.1.4 Main Business and Markets Served
      • 7.2 ArQule, Inc.
        • 7.2.1 ArQule, Inc. Bile Duct Cancer Drug Production Sites and Area Served
        • 7.2.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.2.3 ArQule, Inc. Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.2.4 Main Business and Markets Served
      • 7.3 Array BioPharma Inc.
        • 7.3.1 Array BioPharma Inc. Bile Duct Cancer Drug Production Sites and Area Served
        • 7.3.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.3.3 Array BioPharma Inc. Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.3.4 Main Business and Markets Served
      • 7.4 Arrien Pharmaceuticals, LLC
        • 7.4.1 Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Production Sites and Area Served
        • 7.4.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.4.3 Arrien Pharmaceuticals, LLC Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.4.4 Main Business and Markets Served
      • 7.5 Aslan Pharmaceuticals Pte. Ltd.
        • 7.5.1 Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Production Sites and Area Served
        • 7.5.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.5.3 Aslan Pharmaceuticals Pte. Ltd. Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.5.4 Main Business and Markets Served
      • 7.6 Bavarian Nordic A/S
        • 7.6.1 Bavarian Nordic A/S Bile Duct Cancer Drug Production Sites and Area Served
        • 7.6.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.6.3 Bavarian Nordic A/S Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.6.4 Main Business and Markets Served
      • 7.7 Bayer AG
        • 7.7.1 Bayer AG Bile Duct Cancer Drug Production Sites and Area Served
        • 7.7.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.7.3 Bayer AG Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.7.4 Main Business and Markets Served
      • 7.8 Blueprint Medicines Corporation
        • 7.8.1 Blueprint Medicines Corporation Bile Duct Cancer Drug Production Sites and Area Served
        • 7.8.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.8.3 Blueprint Medicines Corporation Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.8.4 Main Business and Markets Served
      • 7.9 Boehringer Ingelheim GmbH
        • 7.9.1 Boehringer Ingelheim GmbH Bile Duct Cancer Drug Production Sites and Area Served
        • 7.9.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.9.3 Boehringer Ingelheim GmbH Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.9.4 Main Business and Markets Served
      • 7.10 Boston Biomedical, Inc.
        • 7.10.1 Boston Biomedical, Inc. Bile Duct Cancer Drug Production Sites and Area Served
        • 7.10.2 Bile Duct Cancer Drug Product Introduction, Application and Specification
        • 7.10.3 Boston Biomedical, Inc. Bile Duct Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
        • 7.10.4 Main Business and Markets Served
      • 7.11 Bristol-Myers Squibb Company
      • 7.12 Celgene Corporation
      • 7.13 CellAct Pharma GmbH
      • 7.14 Cellceutix Corporation
      • 7.15 Cellular Biomedicine Group, Inc.
      • 7.16 Concordia Healthcare Corp.

      8 Bile Duct Cancer Drug Manufacturing Cost Analysis

      • 8.1 Bile Duct Cancer Drug Key Raw Materials Analysis
        • 8.1.1 Key Raw Materials
        • 8.1.2 Price Trend of Key Raw Materials
        • 8.1.3 Key Suppliers of Raw Materials
      • 8.2 Proportion of Manufacturing Cost Structure
      • 8.3 Manufacturing Process Analysis of Bile Duct Cancer Drug
      • 8.4 Bile Duct Cancer Drug Industrial Chain Analysis

      9 Marketing Channel, Distributors and Customers

      • 9.1 Marketing Channel
        • 9.1.1 Direct Marketing
        • 9.1.2 Indirect Marketing
      • 9.2 Bile Duct Cancer Drug Distributors List
      • 9.3 Bile Duct Cancer Drug Customers

      10 Market Dynamics

      • 10.1 Market Trends
      • 10.2 Opportunities
      • 10.3 Market Drivers
      • 10.4 Challenges
      • 10.5 Influence Factors

      11 Global Bile Duct Cancer Drug Market Forecast

      • 11.1 Global Bile Duct Cancer Drug Production, Revenue Forecast
        • 11.1.1 Global Bile Duct Cancer Drug Production Growth Rate Forecast (2019-2025)
        • 11.1.2 Global Bile Duct Cancer Drug Revenue and Growth Rate Forecast (2019-2025)
        • 11.1.3 Global Bile Duct Cancer Drug Price and Trend Forecast (2019-2025)
      • 11.2 Global Bile Duct Cancer Drug Production Forecast by Regions (2019-2025)
        • 11.2.1 North America Bile Duct Cancer Drug Production, Revenue Forecast (2019-2025)
        • 11.2.2 Europe Bile Duct Cancer Drug Production, Revenue Forecast (2019-2025)
        • 11.2.3 China Bile Duct Cancer Drug Production, Revenue Forecast (2019-2025)
        • 11.2.4 Japan Bile Duct Cancer Drug Production, Revenue Forecast (2019-2025)
      • 11.3 Global Bile Duct Cancer Drug Consumption Forecast by Regions (2019-2025)
        • 11.3.1 North America Bile Duct Cancer Drug Consumption Forecast (2019-2025)
        • 11.3.2 Europe Bile Duct Cancer Drug Consumption Forecast (2019-2025)
        • 11.3.3 China Bile Duct Cancer Drug Consumption Forecast (2019-2025)
        • 11.3.4 Japan Bile Duct Cancer Drug Consumption Forecast (2019-2025)
      • 11.4 Global Bile Duct Cancer Drug Production, Revenue and Price Forecast by Type (2019-2025)
      • 11.5 Global Bile Duct Cancer Drug Consumption Forecast by Application (2019-2025)

      12 Research Findings and Conclusion

        13 Methodology and Data Source

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Bile Duct Cancer Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Bile Duct Cancer Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Bile Duct Cancer Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
        At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

        The following manufacturers are covered:
        Ariad Pharmaceuticals, Inc.
        ArQule, Inc.
        Array BioPharma Inc.
        Arrien Pharmaceuticals, LLC
        Aslan Pharmaceuticals Pte. Ltd.
        Bavarian Nordic A/S
        Bayer AG
        Blueprint Medicines Corporation
        Boehringer Ingelheim GmbH
        Boston Biomedical, Inc.
        Bristol-Myers Squibb Company
        Celgene Corporation
        CellAct Pharma GmbH
        Cellceutix Corporation
        Cellular Biomedicine Group, Inc.
        Concordia Healthcare Corp.

        Segment by Regions
        North America
        Europe
        China
        Japan

        Segment by Type
        Cabozantinib S-malate
        Elpamotide
        Exatecan Mesylate
        LY-2801653
        NUC-1031
        Others

        Segment by Application
        Hospital
        Clinic
        Others

        Buy now